Lipid Nanoparticles (LNPs) and Solid Lipid Nanoparticles (SLNs) have an average diameter between 10 and 1000 nanometers and are one of the most clinically advanced non-viral gene delivery systems. They can effectively deliver nucleic acids, overcoming a barrier preventing the development and application of genetic medicines.
Lipid Nanoparticles - our High Pressure Homogenizers
Easy to scale systems from Lab R&D to full production units that can produce a very high number of doses.
High shear processing efficiently creating consistent particle sizes with narrow distributions, increasing product stability and improving processes such as sterilization.
Industry-leading pressures up to 60,000 psi (4200 bar, 420 MPa).
Sophisticated temperature control both pre-processing and post homogenization.
CIP and SIP capability. Full documentation packs, provision of DQ/IQ/OQ.
Easy to use, sterlize and maintain with low ongoing ownership costs.
Pilot - Production Homogenizing System
Lab scale Homogenizer
Wikipedia. Solid lipid nanoparticles (SLNs). There is only one phospholipid layer because the bulk of the interior of the particle is composed of lipophilic substance. Payloads such as modRNA, RNA vaccine or others can be embedded in the interior, as desired. Optionally, targeting-molecules such as antibodies, cell-targeting peptides, and/or other drug molecules can be bound to the exterior surface of the SLN.
Image copyright: By Andrea Trementozzi - Own work, CC BY-SA 3.0.